STUDY OBJECTIVES: Erythrocyte levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (Omega-3 Index) were previously found to be associated with obstructive sleep apnea (OSA) at very low levels (< 5.0%) in only one epidemiologic study. OSA has comorbidities, such as arterial hypertension, heart failure, or major depression, also associated with a low Omega-3 Index. These comorbidities can be improved by increasing intake of EPA and DHA, and thus the Omega-3 Index, preferably to its target range of 8% to 11%. Symptoms of OSA might improve by increasing the Omega-3 Index, but more research is needed. METHODS: In our sleep laboratory, 357 participants with OSA were recruited, and data from 315 participants were evaluated. Three categories of OSA (none/ mild, moderate, severe) were defined based on apnea-hypopnea index. Anthropometrics and lifestyle characteristics (smoking, alcohol, fish intake, omega-3 supplementation) were recorded. Erythrocyte fatty acid compositions were assessed with the HS-Omega-3 Index methodology. RESULTS: The mean Omega-3 Index in all 3 categories of OSA was 5.7%, and no association with OSA was found. There were more male participants with severe OSA (79.7%, P = .042) than females, and participants with severe OSA had a significantly higher body mass index (32.11 ± 6.39 kg/m2, P = .009) than participants with mild or moderate OSA. Lifestyle characteristics were not significantly different. CONCLUSIONS: In contrast to our hypothesis, an Omega-3 Index of 5.7% was not associated with OSA severity. Previously, an Omega-3 Index < 5.0% was associated. Although our results suggest aiming for an Omega-3 Index > 5.7% in an intervention trial with EPA and DHA in OSA, comorbidities of OSA suggest a target range of 8% to 11%.
STUDY OBJECTIVES: Erythrocyte levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (Omega-3 Index) were previously found to be associated with obstructive sleep apnea (OSA) at very low levels (< 5.0%) in only one epidemiologic study. OSA has comorbidities, such as arterial hypertension, heart failure, or major depression, also associated with a low Omega-3 Index. These comorbidities can be improved by increasing intake of EPA and DHA, and thus the Omega-3 Index, preferably to its target range of 8% to 11%. Symptoms of OSA might improve by increasing the Omega-3 Index, but more research is needed. METHODS: In our sleep laboratory, 357 participants with OSA were recruited, and data from 315 participants were evaluated. Three categories of OSA (none/ mild, moderate, severe) were defined based on apnea-hypopnea index. Anthropometrics and lifestyle characteristics (smoking, alcohol, fish intake, omega-3 supplementation) were recorded. Erythrocyte fatty acid compositions were assessed with the HS-Omega-3 Index methodology. RESULTS: The mean Omega-3 Index in all 3 categories of OSA was 5.7%, and no association with OSA was found. There were more male participants with severe OSA (79.7%, P = .042) than females, and participants with severe OSA had a significantly higher body mass index (32.11 ± 6.39 kg/m2, P = .009) than participants with mild or moderate OSA. Lifestyle characteristics were not significantly different. CONCLUSIONS: In contrast to our hypothesis, an Omega-3 Index of 5.7% was not associated with OSA severity. Previously, an Omega-3 Index < 5.0% was associated. Although our results suggest aiming for an Omega-3 Index > 5.7% in an intervention trial with EPA and DHA in OSA, comorbidities of OSA suggest a target range of 8% to 11%.
Authors: Winfried Randerath; Johan Verbraecken; Stefan Andreas; Michael Arzt; Konrad E Bloch; Thomas Brack; Bertien Buyse; Wilfried De Backer; Danny Joel Eckert; Ludger Grote; Lars Hagmeyer; Jan Hedner; Poul Jennum; Maria Teresa La Rovere; Carla Miltz; Walter T McNicholas; Josep Montserrat; Matthew Naughton; Jean-Louis Pepin; Dirk Pevernagie; Bernd Sanner; Dries Testelmans; Thomy Tonia; Bart Vrijsen; Peter Wijkstra; Patrick Levy Journal: Eur Respir J Date: 2017-01-18 Impact factor: 16.671
Authors: Amir Qaseem; Paul Dallas; Douglas K Owens; Melissa Starkey; Jon-Erik C Holty; Paul Shekelle Journal: Ann Intern Med Date: 2014-08-05 Impact factor: 25.391
Authors: Bobak Heydari; Shuaib Abdullah; James V Pottala; Ravi Shah; Siddique Abbasi; Damien Mandry; Sanjeev A Francis; Heidi Lumish; Brian B Ghoshhajra; Udo Hoffmann; Evan Appelbaum; Jiazhuo H Feng; Ron Blankstein; Michael Steigner; Joseph P McConnell; William Harris; Elliott M Antman; Michael Jerosch-Herold; Raymond Y Kwong Journal: Circulation Date: 2016-08-02 Impact factor: 29.690
Authors: Harry B Rice; Aldo Bernasconi; Kevin C Maki; William S Harris; Clemens von Schacky; Philip C Calder Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2016-01-25 Impact factor: 4.006
Authors: Sunita R Cheruku; Hawley E Montgomery-Downs; Susanna L Farkas; Evelyn B Thoman; Carol J Lammi-Keefe Journal: Am J Clin Nutr Date: 2002-09 Impact factor: 7.045
Authors: Paul Montgomery; Jennifer R Burton; Richard P Sewell; Thees F Spreckelsen; Alexandra J Richardson Journal: J Sleep Res Date: 2014-03-08 Impact factor: 3.981